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756 CANNON ET AL
CAPTOPRIL IN CONGESTIVE HEART FAILURE
Ninety-two patients with heart failure refractory to dig-
italis and diuretic therapy had captopril (n = 50) or
placebo (n = 42) added to their therapeutic regimen in
a randomized, double-blind trial. During a 2 week dos-
age titration period, one captopril-treated patient died
of an intracerebral hemorrhage . Over the remaining 10
week evaluation period, 1 captopril-treated patient (2% )
was excluded from the study becauseof treatment failure
as compared with 12 discontinuations (4 deaths and 8
failures [29%]) among the placebo group (p < 0.001).
Eighty percent of patients in the captopril group exhib-
ited some degree of clinical improvement, whereas only
27% in the placebo group did so (p < 0.001). The ther-
apeutic advantage of captopril over placebo was evi-
denced by a mean improvement of 0.52 (2.8 ± 0.1 to
2.3 ± 0.1) in the NewYork Heart Associationfunctional
class value as compared with 0.03 (2.9 ± 0.1 to 2.8 ±
0.1) with placebo (p < 0.001). There was a 24% mean
increase in exercise tolerance with captopril (495 ± 22
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to 614 ± 27 seconds) as compared with 0.4 % with pla-
cebo (480 ± 28 to 483 ± 43 seconds) (p < 0.01); the
captopril group had an increase in the ejection fraction
from a mean baseline value of 0.19 ± 0.02 to 0.22 ±
0.02 as compared with 0.19 ± 0.02 to 0.18 ± 0.002 (p
< 0.05) in the placebo group.
A cohort analysis revealed that improvement in ex-
ercise tolerance with captopril was gradual and pro-
gressive throughout the 12 weeks. Improvement in spe-
cific symptoms of heart failure, that is, dyspnea, fatigue
and orthopnea, and the reduction of edema also were
greater in the captopril-treated patients (p < 0.05 to
p < 0.001). Captopril therapy was well tolerated, al-
thoughsymptomatichypotension after the firstdosecaused
withdrawal of three patients (3% ) from the study. It was
concluded that captopril is an effectiveadjunctive treat-
ment to digitalis and diuretic drugs for patients with
refractory heart failure.
In chronic heart failure, decrea sed contractility of the left
ventricle leads to reduced cardiac output with consequent
systemic arterial and venous vasoconstriction (1,2). This
vasoconstriction , which promote s the vicious cycle of fur-
ther reductions of stroke volume followed by an increased
elevation of vascular resistance, appears to be mediated , in
part , by the renin-angiotensin system (3- 8). The key com-
ponent of this system, the potent vasoconstrictor, angioten-
sin II, also has the effect of stimulating aldosterone secre-
tion, possibly enhancing sympathetic drive and increasing
vasopressin secretion (8-12) . Thus , angiotensin-converting
enzyme inhibition, which prevents the conversion of "in-
active" angiotensin I to angiotensin II, may be beneficial
in congestive heart failure by reducing systemic vascular
resistance and relieving circulatory congestion .
Captopril, an oral angioten sin-converting enzyme inhib-
itor, has been demonstrated in uncontrolled studies (12-20)
to increase cardiac output , reduce vascular resistance and
left ventricular filling pressure and provide greater exercise
tolerance. In uncontrolled studies (17-19 , 21-23), the
hemodynamic improvement was maintained for up to 2 years.
The present multicenter study of refractory congestive heart
failure was conducted to evaluate the clinical efficacy and
safety of captopril using a random double-blind, placebo-
controlled design .
Methods
Study Patients
This trial was conducted in 13 medical research centers
from August 1980 through December 1981. Ninety-two pa-
tients with chronic congestive heart failure refractory to
digitalis and diuretic therapy were randomly assigned to
treatment with either captopril (50 patients) or placebo (42
patients). The age range was 30 to 77 years (four eligible
patients who underwent initiation therapy with captopril
were not randomized to treatment groups [see Safety sec-
tion]) . In these 92 patients, the cause of heart failure was
most commonly ischemic heart disease (56% of patients
treated with captopril and 33% of patients treated with pla-
cebo) followed by primary myocardial disease in 30% of
captopril patients, and 57% of placebo patients. Fifty-four
percent were classified in New York Heart Association func-
tional class III and the remainder were almost always clas-
sified in grade II. The status of congestive heart failure for
most patients was described by investigators as stable (50%
captopril , 57% placebo) or deter iorating (46% captopril ,
43% placebo). The characteristics of patients in each group
are shown in Table 1.
Patients were excluded if they had a supine systolic blood
pressure lower than 95 mm Hg, angina pectoris requir ing
frequent nitrate therapy (> 5 nitroglycerin tablets/wk), hy-
pertension not controlled by diuretics, history of myocardial
infarction within the previous 4 months. hepatic or renal
impairment (serum bilirubin or serum glutamic oxaloacetic
transaminase , or both , more than twice the upper limit of
normal for the laboratory and creatinine clearance of :s 50
mllmin) or uncorrected valvular or pericardial ' disease. In
medical research centers using the gated radionuclide tech-
nique of measuring ejection fraction, patients with an ir-
regular rhythm (atrial fibrillation with irregular ventricular
response or frequent [> lO/minl premature ventricular com-
plexes) were excluded.
To be eligible for entry, patient s had to be capable of
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Table 1. Comparability of Treatment Groups
Treatment Group
Captopril Placebo
Patient Charactenstlcs (n = 50) (n = 42)
Sex
Male 48 (96%) 39 (93%)
Female 2 (4%) 3 (7%)
Age (years)
Mean 60* 55
Range 37 to 77 30 to 73
Duration of CHF (months)
Mean 52 42
Range I to 144 2 to 204
Status of CHF
Improving slowly 2 (4%) o (Oo/c)
Stable 25 (50%) 24 (57%)
Deteriorating slowly 22 (44%) 15 (36%)
Deterioratmg rapidly 1(2%) 3 (7%)
Cause of CHF
Primary myocardial disease 15 (30%) 24 (570/c)
Ischemic heart disease 28 (56%) 14 (33%)
Hypertension 2 (4%) 1(2%)
Valvular disease 5 (10%) 3 (7%)
NYHA funcnonal class
II 22 (44%) 15 (36%)
III 27 (54%) 25 (60%)
IV 1(2%) 2 (5%)
Previous vasodilator therapy
No 22 (48%) 20 (51%)
Yes-none or slight response 21 (45%) 15 (38%)
Yes-fair or good response 3 (7%) 4 (10%)
*The age of the patients In the captopnl group was significantly higher
(p = 0.04) than that of patients In the placebo group.
CHF = congestive heart failure; n = number of patients, NYHA =
New York Heart ASSOCIation.
exercising for at least 3 and no more than 12 minutes on a
treadmill following a modified Naughton multistage pro-
tocol (24) in which no pause for rest was allowed between
stages, The study was approved by the committee on human
research in each of the 13 participating institutions. Written
informed consent was obtained from all patients,
Study Design
Screening and stabilization period. At the beginning
of this period, vasodilator therapy was discontinued and the
maintenance dosage of digitalis and diuretic drugs was ad-
justed upward until the investigator was satisfied that an
optimal regimen had been achieved,
Patients were followed up on an outpatient basis for at
least 2 weeks, during which time one placebo tablet three
times daily was prescribed in addition to the digitalis/diuretic
regimen, After at least I week of this period, an exercise
stress test was performed with an end point of dyspnea or
fatigue, or both. This was repeated at the end of the period.
Ifnecessary, a further test (or tests) was scheduled until two
consecutive tests varied by no more than 2 minutes, Patients
were then admitted to the hospital for a full physical ex-
amination, chest roentgenogram, 12 lead electrocardiogram
and measurement of radionuclide left ventricular ejection
fraction, Blood and urine specimens were taken for a stan-
dard laboratory test panel,
Initiation of therapy with captopril. After the baseline
evaluation, patients remained in the hospital for at least 2
days, during which time captopril therapy was initiated and
the dose titrated to 50 mg three times daily, if tolerated,
(Lack of tolerance was considered to be a significant de-
crease in blood pressure if accompanied by symptoms or
signs of hypotension.) The first dose was 25 mg. Vital signs
were measured with the patient supine and standing before
and at frequent intervals for 4 hours after this and subsequent
dosing during the first 2 days. If the drug was tolerated
adequately, two subsequent 25 mg doses were given. At
the time of discharge, patients were randomly assigned on
a double-blind basis to either captopril or placebo, 25 or 50
mg three times daily. Only those patients not able to tolerate
the 50 mg dose were on the lower dose regimen. To keep
the principal investigator blinded, during this initiation pe-
riod and the first 2 weeks of maintenance therapy, patients
were under the control of a "third party" investigator.
Double-blind maintenance therapy. Patients received
either captopril or placebo for a 12 week double-blind pe-
riod. Visits were scheduled twice weekly for the first 2
weeks and biweekly thereafter. At the first visit, drug tol-
erance was assessed and, if the drug was well tolerated, the
dose was increased to 100 mg three times daily at the second
visit (end of Week 1). The third visit again assessed tol-
erance. The dose employed during Week 2 was maintained
for most patients throughout the remaining 10 weeks of the
study; only 28 patients (30%) received less than 100 mg
three times daily.
After 2, 4, 8 and 12 weeks oftreatment, exercise tolerance
testing and laboratory tests were repeated and patients were
questioned and examined with regard to symptoms and signs
of congestive failure, At the Week 12 visit, radionuclide
imaging and radiography for the cardiothoracic ratio were
repeated, and the physician's overall impressions of the
patient's status compared with the baseline condition were
recorded, Patients were evaluated by the same physician at
each visit. Hematologic variables and a quantitative 12hour
urinary protein determination were measured biweekly.
Apart from the usual reasons for discontinuation, such
as severe adverse reactions or concurrent illness, patients
were removed from the study if considered' 'treatment fail-
ures." This was defined as increasing heart failure that
required therapeutic intervention not permitted by the protocol.
Statistical methods. Patients were considered eligible
for efficacy evaluation if they completed 2 or more weeks
of double-blind treatment. For exercise tolerance times,
functional class ratings, ejection fractions, cardiothoracic
ratios, dyspnea, fatigue, edema and mean values at baseline
and at the end of the double-blind treatment were obtained.
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Table 2. Comparison of Functional Class Rating Changes From
Pretreatment to Time of Last Assessment
NYHA Functional Class
(mean ± SEM and adjusted changes)*
Figure 1. The clinical course of 91 patients in captopril and pla-
cebo groups.
*Adjusted for difference in pretreatment level.
The difference between the two treatment groups is statistically sig-
nificant (p = 0.0004).
SEM = standard erro r of the mean; other abbreviatio ns as 10 Tab le I.
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tional class ratings for all patients in each treatment group
at the time of the last measurement during the course of
double-blind therapy are shown in Table 2. Ratings for
captopril-treated patients improved from a mean baseline
value of 2.8 ± 0 .1 by a mean of 0.52 as compared with a
mean ratings improvement of 0.03 from a mean baseline
value of 2.9 ± 0 .1 for placebo -treated patients . Adjusting
for differences in pretreatme nt values, the degree of change
in captopri l patients was significantly greater (p = 0.0004).
The course of mean functional class changes for patients
with values for weeks 2, 4, 8 and 12 is shown in Figure 2.
At all time points, mean values for patients in the captopril
group were significantly improved over baseline values (p
< 0.00 I), as was the degree of improvement compared with
that of placebo-treated patients (p < 0.05) .
Exercise capacity (Table 3). Exercise tolerance times
were obta ined from 48 of the captopri l-treated patients and
all of the 42 placebo-treated patients . At the time of final
measurement , the mean improvement in exercise duration
in the captopril group was 24% (494 ± 22 to 6 14 ± 27
seconds), which was superio r to that of the placebo group ,
Analysis of covariance methods was used to adjust for dif-
ferences in pretreatment levels to compare the effectiveness
of captopril and placebo .
Cohorts of patients who completed 12 weeks of therapy
in captopril and placebo treatment groups were examined
to evaluate the response change s throughout this period .
The mean functional class ratings and exercise tolerance
times at pretreatment and at weeks 2, 4, 8 and 12 were
obta ined . All post-treatment values were compared with the
baseline values through two-way analysis of variance meth-
ods. An analysis of covariance method was again used to
compare the two treatments with respect to changes from
baseline at each specified time .
For variables recorded as either present or absent. such
as hepatojugular reflux and paroxysmal nocturnal dyspnea,
the preva lences at the beginning and at the end of the study
were obtained for patients in both treatment groups. The
difference betwee n the two groups with respect to changes
in prevalence from baseline was assessed using the Z test.
The standard erro r of the change in prevalence was calcu-
lated using McNemar's approac h (25).
For ratings of overall impressions by both physicians
and patients of the total clinical status. numerical scores
were used (see Results). Comparisons between groups with
respect to these scores were carried out using Student' s
t test.
Double-Blind Evaluation
Of the 92 patients randomly assigned to double-blind
treatment , 9 1 comp leted 2 or more weeks of therapy and
were eligible for efficacy eva luation . One patient assigned
to captopril treatment died of an intracerebral hemorrhage
before the Week 2 visit.
Clinical course. The clinical course of the 91 remaining
patients during double-blind therapy is shown in Figure I .
In the captopril group of 49 patients, 2 failed to complete
12 weeks of therapy; I was discontinued as a treatment
failure (see Methods) and I because of a protocol violation.
Among the 42 placebo-treated patients, 14 failed to com-
plete the double-blind period ; 4 patients died and 8 were
discontin ued as treatment failures. One placebo-treated pa-
tient was withdrawn because of an adverse reaction to pla-
cebo , and one patient was lost to follow-up. The incidence
of treatment failure withdrawals among captopril-treated pa-
tients was significantly less than in the placebo group (prob-
ability [pI < 0 .05), and less than the combined total of
placebo group withdrawals due to deaths plus treatment
failures (p < 0.00 1).
Functional class (Table 2). Of the 47 patients who com-
pleted double-blind therapy with captopri l, 30 (61% of the
original group) had improved New York Heart Association
functional class ratings. Of the 28 placebo-treated patients
who completed this period, to (24% of the original group)
exhibited functional class improvement (Fig. I). Mean func-
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Figure 2. Companson of New York Heart Association (NYHA)
functional class ratings for cohorts of patients (mean ± standard
error of the mean). n = number of patients; p = probability.
Figure 3. Comparison of exercise tolerance times for cohorts of
patients (mean ± standard of the mean).
whose exercise capacities were virtually unchanged (480 ±
23 to 483 ± 43 seconds (p < 0.01). In terms of exercise
stages under the Naughton protocol, captopril-treated pa-
tients exhibited a mean increase in exercise capacity of +
1.0 stage. This was significantly greater than the + 0.4
stage increase of the placebo-treated patients (p = 0.03).
Mean exercise tolerance times for the patients whose ex-
ercise duration was measured at baseline and at each stip-
ulated follow-up time are shown in Figure 3. At all time
points, mean exercise times for patients in the captopril
group were significantly improved over baseline values
(p < 0.001), and at Week 12, over the corresponding time
for placebo-treated patients (p < 0.0 1). At none of the
exercise periods were placebo values significantly different
from baseline values.
In captopril-treated patients, both functional class Im-
provement and exercise duration increases appeared to be
greater in those who entered therapy in functional classes
Table 3. Comparison of Bxercise Tolerance TImes From
Pretreatment to Time of Last Measurement
Exercise Tolerance Time In Seconds
(mean ± standard error of the mean
and adjusted percent change)*
Treatment Post- Adjusted
Group No. Pretreatment Treatment % Change
Captopril 48t 494 ± 22 614 ± 27 24.3%
Placebo 42 480 ± 23 483 ± 43 04%
*Adjusted for difference In pretreatment level. tData were not reported
in one patient.
The difference between the two treatment groups is statistically sig-
nificant (p = 0.007)
Abbreviations as in Table I.
III and IV and whose heart failure was due to primary
myocardial disease as opposed to ischemic heart disease
(Table 4). However, the differences between groups were
not significant at the 0.05 level.
Ejection fraction and cardiothoracic ratio (Table
5). Thirty-three captopril-treated patients and 25 placebo-
treated patients provided pre- and post-treatment radio-
nuclide left ventricular ejection fraction data; similarly, 37
captopril-treated patients and 30 placebo-treated patients
provided data on comparative cardiothoracic ratio changes.
In both cases, improvement in the captopril group was su-
perior with a + 16% mean change compared with - 1.8%
mean change for the radionuclide ejection fraction, and
-2.1% mean change compared with +0.3% mean change
for the cardiothoracic ratio. Only in the former case was
this difference statistically significant (p < 0.05).
Symptoms and signs of congestive heart failure (Table
6). During the course of double-blind therapy, all patients
in the captopril- and placebo-treated groups provided data
suitable for comparing the change in severity of specific
symptoms and signs of congestive heart failure. The symp-
toms compared were dyspnea, fatigue, orthopnea and par-
oxysmal nocturnal dyspnea. The signs compared were the
presence of edema, jugular venous distension and a hepa-
tojugular reflux. In some cases (dyspnea, fatigue, orthop-
nea and edema), mean severity scores were used; they were
obtained by allocating numerical values for the degree of
severity of a variable in each patient and then averaging the
values for the treatment group (Table 6, footnote). For the
remaining variables, the basis of comparison was the percent
of patients in each group having the symptom or sign before
treatment and at the end of the 12 week period. The results
demonstrate a statistically significant superiority for cap-
topril over placebo therapy in relieving dyspnea, fatigue and
760 CANNON ET AL.
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Table 4. Functional Class Improvement and Exercise Tolerance Time Improvement: Cause of Congestive Heart Failure According to
Pretreatment Functional Classification and in Captopril-Treated Patients
Pretreatment
ETI in Seconds (mean ± SEM) NYHA CLASS (mean rating ± SEM)
Characteristic No. Pre Post % Change No. Pre Post Change
NYHA class II 21* 604 ± 26 724 ± 40 20 22 2.5 ± 0.1 2.1 ± 0.1 -0.4
NYHA classes 27 423 ± 24 540 ± 29 28 27 3.0 ± 0.1 2.4 ± 0.1 -0.6
III and IV
Pnmary 15t 505 ± 42 666 ± 52 32 15 2.7 ± 0.1 1.8 ± 0.2 -09
myocardial
disease
Ischemic 27t 492 ± 29 585 ± 35 19 27 2.9 ± 0.1 2.5 ± 0.1 -0.4
myocardial
disease
*Data missing for one patient.
t In six patients, the congestive heart failure was caused by either hypertensive or valvular disease. Also, data were not reported for one patient.
CHF = congestive heart failure; ETI = exercise tolerance time; NYHA = New York Heart Association; Post = after treatment with captopril;
Pre = before treatment with captopnl; SEM = standard error of the mean.
orthopnea and reducing edema. In the case of paroxysmal
nocturnal dyspnea, jugular venous distension and hepato-
jugular reflux, there was a uniform trend of more patients
improving in the captopril-treated group, although the dif-
ferences did not achieve statistical significance.
Throughout the 12 week double-blind period, compari-
sons of symptomatic improvement between the two treat-
ment groups were made by recording and scoring both the
physician's and patient's impression of efficacy. Data were
available for 46 of the captopril-treated patients and 41 of
the placebo-treated patients. The results of these subjective
analyses are shown in Table 7 (scoring method footnoted).
On the basis of average scores, the impression of both phy-
sicians and patients was of a significantly superior symp-
tomatic improvement in the captopril-treated group (p <
0.001). The physicians considered that in the captopril group
80% of patients exhibited some degree of improvement,
whereas in the placebo group only 27% experienced some
improvement. The corresponding impression of patients in
the captopril group was that 81% felt improvement whereas
of those in the placebo group 30% felt improvement.
Under the study protocol, the only additional treatment
permitted was intravenous furosemide for the control of
acute exacerbations or symptoms. Ten patients taking pla-
cebo and two assigned captopril administration required such
intervention; this difference is significant (p < 0.05). During
maintenance therapy, an increase in diuretic dosage was not
permitted, but dosage reductions were possible. Eleven cap-
topril-treated patients had reductions in diuretic dosage, as
did three (7%) placebo-treated patients (difference not
significant) .
Safety
Side effects (hypotensive symptoms). In this study, be-
fore treatment randomization, all 96 eligible patients ini-
tially received 2 days of therapy with captopril (see Meth-
ods). Safety data for captopril thus take into account all
patients for the initiation period, and separately, patients
randomized to captopril therapy for the double-blind period.
Overall, captopril was well tolerated. Side effects, when
they did occur, were usually mild and transient.
During the 2 day initiation period. captopril was dis-
continued in three patients (3%) because of symptomatic
hypotension (captopril was discontinued in a fourth patient
because of the unrelated development of pneumonia; this
patient died several days later). All three hypotensive pa-
tients experienced faintness on standing after the first 25 mg
dose. Supine blood pressures decreased within 1'12 to 2 hours
from 112/84 to 76/50, 133/78 to 42/28 and 120/70 to 76/
50 mm Hg, respectively. All three patients recovered rapidly
Table 5. Comparative Changes in Radionuclide Left Ventricular Ejection Fraction and Cardiothoracic Ratio
Radionuclide Ejection Fraction Cardiothoracic Ratio
Treatment
(mean ± SEM) (mean ± SEM)
Group No. Pre Post % Change* No. Pre Post % Change*
Captopnl 23 0.19 ± 0.02 0.22 ± 0.02 16.2t 37 0.56 ± 0.01 0.55 ± 0.01 -2.U
Placebo 25 0.19 ± 0.02 0.18 ± 0.02 -18 30 0.57 ± 0.01 0.58 ± 001 0.3
*Adjusted for differences in pretreatment levels. tThe difference between the two treatment groups IS statistically significant (p < 0.05). tThe
difference between the two treatment groups is not significant (p > 0.05)
Post = after treatment with captopril; Pre = before treatment with captopnl.
JACC Vol 2. No 4
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Table 6. Comparative Change in Symptoms and Signs of Congestive Heart Failure in Captopril and Placebo Treatment Groups
Durin g 12 Week Double-Blind Therapy
Captopril Group (n = 49)
Symptoms and Signs of
CHF
Mean score
Dyspnea*
Fatlgue*
Orthopneat
Edcmaj
% of patients with
Paroxysmal nocturnal dyspnea
Jugular venous distension
Hepatojugular reflux
Pre
28
2.7
0.3
0 5
120/(
440/(
400/(
Post
2.2
2. 1
0.2
02
6%
270/(
25o/c
Placebo Group (n = 42)
Pre Post
2.8 2.8
2.7 26
0 4 0.5
0 4 0 7
260/( 26o/c
520/( 450/(
52% 45o/c
p Value for
DIfference
Between
Treatments
< 0.001
< 0.001
< 0.05
0001
NS
NS
NS
*Score: I 0 = none; 2.0 = slight. 2.5 = moderate; 3.0 = marked; 4 0 = disabling. tScore' 0 = none, I = 450 elevation; 2 = >45 0 elevation.
t Score. 0 = none; I = trace; 2 = I + to 2+. 3 = 3 + to 4 +
CHF = congestive heart failure: n = number of patients: NS = not significant (p > 0.05); P = probability, Post = after treatment with captopril;
Pre = before treatment With captopnl.
without intervention. One of these patients was given a
second dose of 12.5 mg 6 hours later; the supine blood
pressure decreased from 88/50 to 60/40 mm Hg after I \12
hours. Captopril was discontinued in this patient at his own
request because of the recurrence of faintness on standing.
Apart from these three patients, mild clinical symptoms of
hypotension (dizziness and lightheadedness) after the first
dose were reported for a further 29 patients (30%) . All 29
wereable tocontinue therapy, but in some cases withdosage
reductions. With subsequentdoses during this 2 day period,
12 of the 29 patients experienced symptoms that either de-
creased, did not recur despite dose increases or recurred
transiently. During the 2 day initiation period, another 15
patients (16%) who had not experienced symptoms after the
first dose did so after one or more subsequent doses.
In the course of double-blind therapy, 18 (36%) of the
50 patients randomized to captopril therapy experienced
hypotensive symptoms. These were usually mild in nature,
responding to reductions in dosage of captopril or diuretic
drug. or both. and in some cases resolving with no alteration
in treatment. One patient experienced lightheadedness and
occasional blurring of vision throughout the full 12 weeks
of the study. Only two captopril-treated patients who ex-
perienced hypotensive symptoms in the double-blind period
had not had similar symptoms at some time during the 2
day initiation period. Eight (25 %) of the 42 placebo-treated
patients experienced hypotensive symptoms in the double-
blind period. Three of these patients had similar symptoms
during their initial prerandomization captopril therapy , The
number of patients in each group affected by hypotensive
symptoms in the double-blind period was not significantly
different. After the first dose of 25 mg in 91 of the 96
patients, the mean arterial pressure decreased from a pre-
treatment level of 87 to 68 mm Hg (-21%, p < 0.001).
(Three patients received initialdoses other than 25 mg. Data
were missingfor 2 patients.). In contrast, decreases in mean
arterial pressurefrom baseline levels for all captopril-treated
patients at Weeks 2 through 12 ranged from 4 to 9%.
Adverse reactions. During the double-blind period of
the study. no patients in the captopril-treated group were
Table 7. Physic ians' and Patients' Global Impressions of Symptomatic Effect of Captopril and Placebo
Physicians' Impression Patients' Impression
Degree of
Improvement
Great
Moderate
Slight
Unchanged
Worse
Mean secret
Captopril
(n = 46)*
4 (8 7%)
15 (32.6o/c)
18 (39.1%)
8 (17.4%)
I (2.20/()
1.3 ~
Placebo
(n = 4 \)*
I (2 4o/c)
6 (14.6%)
4 (9.8o/c)
16 (39 Oo/c )
14 (34.2%)
0.1
Captopril
(n = 46)*
8 (174%)
17 (37 0%)
12 (26. 1%)
7 m .2'k)
2 (4 .4%)
1.5 ~
Placebo
(n = 40)*
5 (12.5%)
6 (15.0%)
1(2 5%)
13 (32.5%)
15 (37 5%)
0.3
*Data were not reported for one patient. t Data were not reported for two patients. t Score. + 3 = great. +2 moderate; + I = slight, 0 =
unchanged; - I = worse. §The difference between the two treatment groups is statisucally significant (p < 0.001)
n = number of patients
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discontinued because of adverse reactions (Fig. I). One
placebo-treated patient was discontinued because of fatigue
and unstable gait, thought to be treatment-related. Two pa-
tients (4%), each receiving a daily dose of 150 mg of cap-
topril, developed a skin rash (as did one patient in the
placebo group). In each case, the rash was transient and the
patients continued in the study. Three patients (6%) com-
plained of mild taste alteration with captopril, but for two
of them (both receiving 300 mg/day) this was transient. In
the third patient (75 mg/day), the taste alteration continued
until the end of the trial.
One captopril-treated patient with compromised renal
function had worsening of azotemia. This patient entered
the study with a serum creatinine level of 1.3 mg/dl and a
blood urea nitrogen of 34 mg/dl. By Week 4 of the double-
blind period, the serum creatinine was 2.7 mg/dl and the
blood urea nitrogen was 75 mg/dl. At the conclusion of the
double-blind period, the serum creatinine and blood urea
nitrogen were, respectively, 1.9 and 71 mg/dl. The patient
continued on captopril therapy after the termination of the
study.
Effects on laboratory determinations, Comprehen-
sive blood chemistry studies, complete blood counts and
urinalyses were performed in all patients before and during
therapy. The effect of captopril on serum potassium was
examined. The mean serum potassium level of the captopril-
treated patients increased from 4.1 to 4.3 mfiq/liter, which
was significantly greater than the mean increase (3.8 to 3.9
mEqlliter in the placebo-treated group (p < 0.05). Potas-
sium supplementation was at the discretion of individual
investigators. Thirty-eight (76%) of the patients randomized
to captopril therapy were receiving potassium supplements,
as were 25 (60%) in the placebo group.
Supplements were discontinued in six of the captopril
group and in three of the placebo group. No captopril-treated
patients became hypokalemic, whereas three placebo-treated
patients (all receiving potassium supplements) developed
serum potassium levels below 3.5 mEq/liter. None of these
treatment group differences were statistically significant. In
the case of serum sodium levels, there were no signifi cant
or obvious differences between the two treatment groups
during the study period. The mean serum uric acid level in
the captopril group decreased by 6.6% compared with an
8% increase in the placebo group, and the mean serum
bilirubin level decreased by 24% compared with a 1.4%
mean increase in placebo-treated patients. Both these treat-
ment differences are statistically significant (p = 0.0 I).
Twenty-five (53%) of the 47 captopril-treated patients
who completed the double-blind period were receiving a
total daily dose of 300 mg. The average daily dose of all
47 patients was 229 mg at Week 2 and 221 at Week 12.
During the course of this 3 month study, no patients de-
veloped leukopenia, neutropenia or proteinuria.
Discussion
Clinical effects on heart failure. This is the largest
placebo-controlled study reported to date of any vasodilator
drug used in the treatment of heart failure. In this study,
comparison of captopril and placebo (both added to a fi xed
diuretic/digitalis regimen) for severe heart failure demon-
strated the efficacy of captopril by significant improvements
in New York Heart Association functional class ratings,
exercise tolerance times and the physicians' and patients'
impressions of symptoms. Corresponding with this evidence
for functional improvement was greater alleviation in the
captopril group of specifi c symptoms and signs of heart
failure, including dyspnea, fatigue, orthopnea and edema.
A significant increase in the left ventricularejection fraction
at rest in the captopril group provides evidence that the
symptomatic improvement can, at least in part, be attributed
to improved left ventricular performance.
This study was not designed to examine the effect of
captopril on mortality from congestive heart failure. None-
theless, the loss of 12 patients from the placebo group (4
who died and 8 with worsening heart failure) during the 3
month double-blind follow-up period and only 2 in the cap-
topril group (l early death and I treatment failure) raises
the possibility that captopril may be effective in altering the
natural history of the syndrome.
Role of etiology of heart failure. Although an imbal-
ance in randomization led to a predominance of patients
with ischemic heart disease in the captopril group and a
preponderance of primary myocardial disease in the placebo
group, it is unlikely that this contributed to the therapeutic
efficacy of captopril. Indeed, when efficacy was evaluated
on the basis of etiology, it appeared that captopril was, if
anything, more effective in the primary myocardial disease
group than in the ischemic heart group.
Adverse effects. Hypotension, after the first few doses,
was the most commonly occurring adverse effect of cap-
topril, resulting in the withdrawal of 3% of the patients.
However, there was a rapid attenuation of this initial hy-
potensive response as evidenced by the fact that from Weeks
2 through 12, the mean arterial pressure decrease in cap-
topril-treated patients (more than half of whom were re-
ceiving 300 mg daily) ranged from 4 to 9%, in contrast to
21% after the fi rst 25 mg dose. Also, once the patients were
established on a maintenance dose, hypotension was no
more common amongthe captopril-treated patients thanamong
their placebo-treated counterparts. Despite the initial de-
creases in blood pressure with captopril, clinical symptoms
of hypotension, if evident at all, were usually minimal, even
when blood pressure reductions were relatively large. Sharpe
et al. (21) showed that the hypotension induced by captopril
in some patients with heart failure can be minimized by
employing starting doses of as low as 6.25 mg three times
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daily. Hypotension also may be avoided by reducing or
interrupting diuretic therapy before commencing captopril,
because diuretic drugs may have the effect of increasing
plasma renin activity and, thus, increasing the sensitivity to
converting enzyme inhibition.
The favorable effect of captopril on potassium balance,
and the clearance of edema in patients already receiving
"optimal" doses of digitalis and diuretic drugs, may be due
to suppression of aldosterone secretion. However, the pos-
sibility of inducing hyperkalemia in an occasional patient
(especially if the diuretic dose is decreased) should be con-
sidered. The absenceof hyperaldosteronism duringcaptopril
therapy also could contribute to the apparent absence of the
attenuation of therapeutic response observed with other
vasodilators (26).
Therapeutic implications. The therapeutic efficacy and
low incidence of serious side effects observed in this study
suggest that captopril may be useful as adjunctive manage-
ment in patients with severe heart failure refractory to ther-
apy with digitalis and diuretic drugs. This study provides
no evidence for the effectiveness of captopril as compared
with other vasodilators used to treat heart failure, nor does
it address the use of captopril in patients whose symptoms
are relieved and exercise tolerance normalized while on
treatment with digitalis and diuretic drugs.
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